Last updated: February 16, 2026
What is NDC 00832-0595?
NDC 00832-0595 corresponds to Tremfya (guselkumab). It is a prescription biological drug used for treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and Crohn’s disease. It is marketed by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary.
Market Size and Growth Trajectory
Current Market Landscape
-
The global psoriasis market was valued at approximately $4.3 billion in 2022 and is projected to reach $6.5 billion by 2030 [1]. This growth is driven by increasing prevalence, expanding indications, and the introduction of novel biologics.
-
The biologics segment accounts for roughly 70% of market revenue within dermatology therapies, with guselkumab holding a significant share due to its efficacy and safety profile.
Prevalence and Demand
-
Psoriasis affects around 2-3% of the global population; in the US, approximately 7.5 million people have psoriasis [2].
-
Psoriatic arthritis affects about 30% of psoriasis patients [3].
-
Crohn’s disease affects roughly 3 million Americans and is increasing in prevalence [4].
Competitive Position
-
Guselkumab competes directly with other IL-23 inhibitors such as Skyrizi (risankizumab) and uckira (tildrakizumab), as well as IL-17 inhibitors and TNF-alpha blockers.
-
The drug’s clinical profile—high efficacy with sustained response—increases preferential prescribing.
Pricing Trends and Projections
Current Pricing
-
List price per injection: approximately $6,500–$7,000 based on wholesale acquisition costs (WAC), with typical treatment regimens involving an initial dosing period of weekly injections for 4 weeks, followed by maintenance every 8 weeks.
-
Annual treatment cost: averages $48,000 to $84,000 depending on dosing frequency and patient adherence.
Reimbursement Landscape
-
Medicare and private payers restrict access based on coverage criteria, influencing overall market penetration.
-
Rebates and discounts lower the effective price by roughly 20–30%, impacting net revenue.
Future Price Trends
-
Reimbursement pressures and biosimilar entry are unlikely to impact guselkumab directly due to its patent protection until at least 2029.
-
Price inflation is expected to stabilize at an annual rate of 2-3% through 2030, assuming no major policy shifts.
Patent and Regulatory Outlook
-
The patent for guselkumab in the US expires around 2029, opening potential biosimilar competition afterward.
-
Pending biosimilar approvals from Indian and European manufacturers could introduce alternatives at a 40-60% lower cost.
-
Janssen's strategy involves expanding indications and improving formulations, which could support maintaining higher prices longer.
Sales Forecasts and Revenue Projections
| Year |
Estimated Market Penetration |
Sales (USD Millions) |
Assumptions |
| 2023 |
25% market share |
$1.2 billion |
Based on existing market share |
| 2025 |
35% market share |
$1.8 billion |
Increased adoption, coverage gains |
| 2027 |
40% market share |
$2.2 billion |
New indications, competitive strength |
| 2030 |
45% market share |
$2.6 billion |
Stabilization and wider access |
Note: These figures assume conservative uptake with minimal biosimilar competition before patent expiry.
Key Risks and Variables
-
Biosimilar entry post-2029 could reduce prices and sales.
-
Payer policies and drug access restrictions influence market penetration rates.
-
New treatments (e.g., oral JAK inhibitors) could compete for market share.
-
Clinical trial outcomes or safety signals may affect drug utilization.
Summary
The market for guselkumab (NDC 00832-0595) is growing steadily, driven by its efficacy in treating psoriasis, psoriatic arthritis, and Crohn’s disease. Current average annual cost is approximately $50,000–$85,000 per patient, with sales projected to reach around $2.6 billion in 2030 under conservative assumptions. Price stability until patent expiry in 2029 is expected, with potential declines thereafter due to biosimilar competition. Continued expansion of indications and patient access strategies support revenue growth through the next several years.
Key Takeaways
-
The psoriasis biologics market is expanding, with guselkumab commanding significant market share due to its clinical profile.
-
Pricing remains high but stable, with limited immediate downward pressure.
-
Patent expiration in 2029 may trigger biosimilar penetration, impacting future revenue.
-
Market growth depends on expanding indications, payer policies, and competitive dynamics.
-
Biosimilar entry remains the chief long-term risk.
FAQs
1. How does guselkumab’s pricing compare to similar biologics?
Guselkumab’s annual cost (~$50,000–$85,000) aligns with other IL-23 inhibitors like risankizumab, which average around $60,000. IL-17 inhibitors tend to be slightly lower but vary by manufacturer.
2. What factors could accelerate sales growth?
Expansion into additional indications, improved patient access, and increased prevalence contribute to faster adoption.
3. What impact will biosimilars have after 2029?
Expected biosimilar entry could lower prices by 40–60%, reducing revenue per patient and market size unless new uses or formulations justify sustained higher prices.
4. How significant is market share loss due to biosimilars?
Loss could range from 20–50% in revenue, depending on biosimilar uptake and formulary acceptance.
5. What is the potential for new competitors?
Novel oral therapies and other biologics could challenge guselkumab’s market, particularly if they offer comparable efficacy at reduced costs.
Citations
[1] Grand View Research. “Psoriasis Market Size & Share Analysis.” 2022.
[2] American Academy of Dermatology. “Psoriasis Prevalence and Statistics.” 2022.
[3] Gladman DD. “Psoriatic arthritis epidemiology.” Rheumatology, 2021.
[4] Crohn’s & Colitis Foundation. “Crohn’s Disease Facts and Figures.” 2022.
